CBT

Cabot Corporation 10-Q Summary: Quarter Ended June 30, 2004

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for Cabot Corporation for the three and nine months ended June 30, 2004. Cabot is a global specialty chemicals company operating primarily through three segments: Chemical Business, Cabot Supermetals, and Specialty Fluids. The company reported strong volumes in its Chemical and Supermetals businesses, supported by cost improvements from its "excellence" initiative.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated net sales increased 5% in the quarter and 7% for the nine-month period, driven by volume increases in the Chemical Business and favorable foreign currency translation.
• Profitability Surge: Net income turned from a $5 million loss in Q3 2003 to a $42 million profit in Q3 2004. This improvement is largely due to a $47 million increase in gross profit and a significant reduction in "certain items" (charges) compared to the prior year.
• Expense Reduction: Selling and administrative expenses decreased $26 million year-over-year in the quarter, and Research and technical expenses dropped $14 million, primarily due to the absence of a $14 million in-process R&D write-off recorded in 2003.
• Segment Performance:
  • Chemical Business: Sales up 9% and profit up 50% due to higher volumes in carbon black and fumed metal oxides.
  • Supermetals: Sales down 7% due to the expiration of intermediate product contracts, but profit rose 29% due to lower operating costs and higher tantalum powder volume.

Guidance, Outlook, and Risks

• Outlook: Management expects the 2004 annual tax rate on continuing operations to be 25%. Capital expenditures for fiscal 2004 are projected to be approximately $130 million, with an anticipated increase in fiscal 2005 to expand capacity in China and other growing regions.
• Restructuring: The company initiated a European restructuring plan in May 2003. Total estimated pre-tax charges are $65 million. As of June 30, 2004, $50 million has been recorded, with an additional $6 million expected over the next 9-12 months. A $10 million reserve remains for severance and asset retirement obligations.
• Legal Contingencies:
  • Respirator Claims: A $20 million reserve exists for liabilities related to an acquired safety respiratory products business (American Optical Corporation), involving approximately 90,000 pending claims.
  • Environmental: A $24 million reserve is held for environmental remediation costs, primarily related to divested businesses.
  • Antitrust/Litigation: The company is involved in antitrust suits regarding its carbon black business and a supply agreement dispute with AVX Corporation. Management believes these will not have a material adverse effect in the aggregate.
• Supply Chain Risk: Cabot is in arbitration with Sons of Gwalia Ltd. regarding the terms of a renewed long-term tantalum ore supply agreement. Negotiations continue, but the outcome is uncertain.

Investor Verification Checklist

• Respirator Liability Reserve: Verify the adequacy of the $20 million reserve against the 90,000 pending claims and the methodology used by the external expert (HR&A).
• Restructuring Progress: Monitor the execution of the European restructuring plan and the timing of the remaining $6 million in expected charges.
• Tantalum Supply Agreement: Track the status of the arbitration with Sons of Gwalia and the potential impact on raw material costs or supply continuity.
• Carbon Black Margins: Assess the sustainability of margin improvements given the noted decline in contract-related prices and feedstock cost adjustments.
• Investment Portfolio: Review the $65 million purchase of available-for-sale securities and the associated yield expectations versus market risk.